December 18, 2008 3:08 PM
- Text
Could Roche-Genentech Deal Price Actually Be Getting Lower?
(MoneyWatch)
Is the acquisition price for Roche to buy Genentech actually getting cheaper? That is the tantalising notion raised in a column in the FT today. BNET readers will remember that the Roche-Genentech deal is conspicuous by its absence because Roche literally couldn't find enough money to borrow to take care of the $44 billion cost of its $89-a-share bid.
Genentech's stock price hit the roof at $98 in the summer as the board rejected Roche's first overture. Holders expected the larger company to come back with a sweeter offer ... but then, history happened. Genentech has been grinding along at between $76 and $80 over the last few days. That means the $89 bid suddenly looks a lot sweeter -- assuming Roche can raise the money, which so far it cannot.
The FT makes this suggestion:
Is the acquisition price for Roche to buy Genentech actually getting cheaper? That is the tantalising notion raised in a column in the FT today. BNET readers will remember that the Roche-Genentech deal is conspicuous by its absence because Roche literally couldn't find enough money to borrow to take care of the $44 billion cost of its $89-a-share bid.Genentech's stock price hit the roof at $98 in the summer as the board rejected Roche's first overture. Holders expected the larger company to come back with a sweeter offer ... but then, history happened. Genentech has been grinding along at between $76 and $80 over the last few days. That means the $89 bid suddenly looks a lot sweeter -- assuming Roche can raise the money, which so far it cannot.
The FT makes this suggestion:
The original plan was to raise up to $45bn, allowing for a margin for manoeuvre, including the option of a modest price rise from its original $89-a-share bid for Genentech. With Genentech now trading at about $77 a share, the markets are clearly sceptical about the probability of a successful bid at the current price.
In current market conditions, Genentech's board of directors might want to reconsider their rejection of Roche's bid. There again, with many months likely required for it to raise the money, Roche itself might want to return with a lower price, or call off the proposal completely for now.
That would take some swallowing of pride. But if time is theoretically on Roche's side, with no one else likely to bid, the current impasse is a festering wound that does little for the morale of Genentech's employees or shareholders.That would be an amazing turn of events: Roche holders, chagrined at having missed their chance at $89, being humbled by the stock market crash into taking something closer to $80 ... which, painfully, was the price before Roche came along.
- For more, see: BNET's Worst-Case Scneario for the Roche-Genentech Bid
Latest Now in MoneyWatch
- Insurers respond cautiously to contraceptive plan
- Judge: Legally, breastfeeding not related to pregnancy
- Budget deficit drops to $27 billion in January
- Why the Powerball Jackpot is part of my investment strategy
- Is the new VW Beetle diesel worth the money?
- Consumer sentiment highlights risks to recovery
- Valentine blues? 10 best cities to be single
- December trade deficit widens to $48.8 billion
- Alcatel-Lucent returns to profit in 2011
- 6 things never to say in a performance review
- $26B mortgage deal: Who gets the money?
- Friendly's CEO steps down
- Quarterly loss hits $3.3B at Postal Service
- Greeks rail against cuts as EU demands more
- 6 things you should never share on Facebook
- Make moves now to increase financial aid
- Valentine's Day: 9 places to save
Latest CBS News Headlines
on Facebook
on CBS News
- Haiti 'Baby Doc' case spurs claim of gov't sway
- Haiti 'Baby Doc' case spurs claim of gov't sway
- Rio police strike exposes marred institution
- Argentine rights workers to Spain: lay off Garzon
on Facebook
- Adele sings a cappella for Anderson Cooper
- Beyonce and Jay-Z post first photos of Blue Ivy Carter
- Adele sings a cappella for Anderson Cooper
on CBS News






